Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri To Go Before Advisory Committee On March 7

This article was originally published in The Pink Sheet Daily

Executive Summary

Committee discussion will include multiple sclerosis therapy’s proposed risk management plan and possible return to market.
Advertisement

Related Content

Tysabri Relatively Safe For Short-Term Use, NEJM Concludes
Tysabri Relatively Safe For Short-Term Use, NEJM Concludes
FDA Clears Tysabri For Limited Clinical Use
FDA Clears Tysabri For Limited Clinical Use
Biogen Idec/Elan Resubmit Tysabri With New Risk Management Program
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan

Topics

Advertisement
UsernamePublicRestriction

Register

PS063079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel